This page shows what was measured, who it was measured in, and what that does not settle.
What Lansoprazole does in the body
Stomach and duodenal ulcers, reflux that has damaged the gullet, and prevention of ulcers caused by anti-inflammatory painkillers
Lansoprazole is swallowed inside granules that survive stomach acid, are absorbed from the small intestine, and travel round in the blood. It has no effect anywhere in the body until it drifts into the acid-secreting channel of a stomach cell, which is the only place acidic enough to activate it. There the acid rearranges it into a reactive form that bonds permanently to the pump making the acid, so that pump never works again and the cell must build a new one. It suppresses acid extremely well and it does nothing at all to a bacterium or to a painkiller, which is why an ulcer with either of those causes heals and then returns.
What happened in people
Helicobacter pylori eradication 94% on lansoprazole with clarithromycin and amoxicillin against 2% on lansoprazole alone, with six-month ulcer recurrence 7% against 69%
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
That infant crying attributed to reflux responds to acid suppression, refuted by an exactly identical placebo response rate
Where it acts
Gastric parietal cell — the secretory canaliculus, reached through the bloodstream after enteric-coated release in the small intestine
Kind of result
The kind of result is not recorded
Supervision
RNAWiki has not recorded a supervision or regulatory status for this substance.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 0K5C5T2QPG · read 2026-08-29
Its recorded molecular formula is C16H14F3N3O2S, weighing 369.37.
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 156 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Absolute difference
An absolute difference is how many more people in a hundred were affected.
A picture of it, and where the picture fails
It is like counting heads in two rooms of a hundred.
Where that stops being true. Heads are easy to count. Study results carry a margin of error too.
What people get wrong. It is confused with a percentage change, which can look far larger.
The arithmetic difference in event rates between arms.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
What happened in people◇Read from sources, not yet reviewed
What was measured, goal by goal
One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.
Registered studies list 39 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.
There is no single score. A strong test result and a weak life result are different facts.
Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
Goal
Life outcome
What a body can do
How a person feels
A test result
A step in the body
Harms
How long
Who was studied
Pain
∅Nothing in the sources checkedNo registered study lists a life outcome for this goal.
∅Nothing in the sources checkedNo registered study lists a performance measure for this goal.
…Waiting for a reviewer1 registered symptom measure.
∅Nothing in the sources checkedNo registered study lists a test result for this goal.
∅Nothing in the sources checkedNo registered study lists a body-step measure for this goal.
—Not recordedHarms were not a registered measure for this goal.
—Not recordedNo finished study window is recorded.
…Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Pain
time to analgesia; pain reduction
Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.
What each mark on this table means
∅ Nothing in the sources checked
No registered study lists a life outcome for this goal.
… Waiting for a reviewer
1 registered symptom measure.
— Not recorded
Harms were not a registered measure for this goal.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Eradication of Helicobacter pylori at 4 to 6 weeks after therapy, and duodenal ulcer recurrence at six months
✓ The study showed what it set out to show
Who was studied
Lansoprazole triple against dual therapy and monotherapy for Helicobacter pylori
Eradication 94% (44 of 47) on triple therapy against 2% (1 of 53) on lansoprazole alone, P<=0.05 for triple against each dual and each dual against monotherapy. Ulcer recurrence at six months 7% against 69%.
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. The monotherapy arm is the interpretable result and it is rarely quoted: acid suppression alone did not clear the organism and the ulcer came back in more than two thirds of patients.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral delayed-release capsule, orally disintegrating tablet containing enteric-coated microgranules, and delayed-release oral suspension
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
44 of 81 (54%) responders in each group — identical
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Serious adverse events, particularly lower respiratory tract infections, occurred in 10 infants on lansoprazole against 2 on placebo (P=0.032). Treatment-emergent adverse events were 62% against 46% (P=0.058).
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral delayed-release capsule, orally disintegrating tablet containing enteric-coated microgranules, and delayed-release oral suspension
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
Change in Asthma Control Questionnaire score over 24 weeks in children with poor asthma control on inhaled corticosteroids and without overt reflux symptoms
Mean difference in change 0.2 units (95% CI 0.0 to 0.3), against a 0.5-unit threshold for clinical meaning
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Respiratory infections were more common on lansoprazole (relative risk 1.3, 95% CI 1.1 to 1.6). The pH-documented reflux subgroup, 43% of the 115 tested, showed no benefit either.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral delayed-release capsule, orally disintegrating tablet containing enteric-coated microgranules, and delayed-release oral suspension
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
Proportion free of endoscopic gastric ulcer at 12 weeks in Helicobacter-negative long-term NSAID users with prior gastric ulcer
✓ The study showed what it set out to show
Who was studied
Lansoprazole against misoprostol for NSAID ulcer prevention
How many people
537
Study design
Phase 3, randomised, double-blind, active- and placebo-controlled
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
Placebo 51% (95% CI 41.1 to 61.3), misoprostol 93% (87.2 to 97.9), lansoprazole 15 mg 80% (72.5 to 87.3), lansoprazole 30 mg 82% (75.0 to 89.6); both lansoprazole arms beat placebo at P<0.001
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Misoprostol beat lansoprazole on the endoscopic endpoint and lost on tolerability. Counting early withdrawals as failures, both active strategies came out at 69% against 35% for placebo — a reframing that changes the conclusion.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral delayed-release capsule, orally disintegrating tablet containing enteric-coated microgranules, and delayed-release oral suspension
Interval reported. 95% CI 41
Written into the record, not signed off as a reviewed claim.
RNAWiki holds 4 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.1 registered measure of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
■Symptoms and quality of lifeEvidence recorded. Pain, tiredness, mood, sleep, as the person rated it.1 registered measure of this kind.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.4 registered measures of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.1 registered measure inside human tissue.
□AnimalsNo evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.No animal record is stored.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Lansoprazole
What a person takes: Oral delayed-release capsule, orally disintegrating tablet containing enteric-coated microgranules, and delayed-release oral suspension.
The measurement behind this step
Every form protects the drug from gastric acid, because the free base is destroyed by it within minutes. The orally disintegrating tablet exists so the drug can be given to small children and to people who cannot swallow capsules, without breaking the enteric coat — the tablet disperses while each microgranule inside it stays sealed.
Getting in
Coated granules that survive the stomach
The drug is destroyed by stomach acid, so it travels inside granules with an acid-proof shell. The orally disintegrating tablet melts on the tongue, but each granule inside it keeps its shell intact.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Enteric-coated microgranules release above pH 5.5 in the duodenum. Oral bioavailability is above 80%, and food substantially reduces absorption. Plasma half-life is about 1.5 hours, far shorter than the duration of effect.
It enters the blood from the small intestine and reaches every tissue in the body, where it does nothing at all. It has no receptor and no target it recognises.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Circulating lansoprazole is a neutral weak base, about 97% protein bound, with no meaningful reversible affinity. It is the most lipophilic of the four in this file, with a logP near 3.7, which speeds diffusion into the canaliculus but does not give it a target anywhere else.
It diffuses into the acid-secreting channel of the stomach cell, picks up a proton, and becomes electrically charged. A charged molecule cannot cross back out through the membrane.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Pyridine pKa near 4. Protonation in a compartment at pH 1 gives roughly thousandfold accumulation relative to plasma, achieved without any transporter. No other compartment in the body is acidic enough to trap it in this way.
A second proton triggers a rearrangement into a highly reactive form that grabs the first sulfur atom it meets. That form survives for a fraction of a second, so it cannot leak out and react anywhere else.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Rearrangement gives a tetracyclic cyclic sulfenamide, a short-lived electrophile with high affinity for accessible cysteine thiols. Its half-life at canalicular pH is measured in seconds, which is the structural basis of the drug’s tissue selectivity.
It bonds permanently to the pump. That pump is finished, and acid production only recovers when the cell has built replacements, which takes days.
╌╌Measured in animals. A result in animals says what to test next. It does not say what happens in people.
The measurement behind this step
The sulfenamide forms disulfides with cysteine 813 and, for this molecule, also cysteine 321 on the luminal face of the H+/K+-ATPase alpha subunit. Inhibition is reversed in vitro by dithiothreitol. Recovery in vivo depends on pump resynthesis with a half-life near 50 hours.
It has no effect on the bacterium that causes most duodenal ulcers, no effect on the prostaglandin that painkillers strip away, and no effect on asthma or on a crying baby. Every one of those was tested and every one came back negative.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
Two weeks of monotherapy eradicated Helicobacter pylori in 1 of 53 patients, with 69% ulcer recurrence at six months. Misoprostol, which replaces the missing prostaglandin, left 93% of NSAID users ulcer-free against 80 to 82% for lansoprazole. In asthma the Asthma Control Questionnaire difference was 0.2 units against a 0.5-unit threshold, and in infants the response rate was identical to placebo at 54%.
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 6 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
pain reduction
Measured
Things only a test, a scale or a device shows.
serum urate 5 0 / at month 3
area under the concentration time curve
cmax maximum observed plasma concentration for bismuth
combined gene expression of cox 2 tumour promoting genes
maximum observed plasma concentration
Meaningful
Things that change how a life goes, not only a number.
hospitalization for community acquired pneumonia
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (32)
pharmacokinetic analysis
intragastric 24 hour ph
lymphocyte count
time to analgesia
c peptide
gerd symptoms
cmax
auc0 t
auc0 inf
2 hour c peptide auc in response to mmtt
recurrent ulcer bleeding
bioequivalence based on cmax and auc parameters
incidence of treatment emergent adverse events
eradication rate of helicobacter pylori
frequency of adverse drug reactions
reporting one or more adverse drug reactions
reporting one or more serious adverse drug reactions
helicobacter pylori eradication
rate of h pylori eradication
count of agreeing to volunteer for the study
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What it would be like to take◇Read from sources, not yet reviewed
How long anything takes
Nine different lengths of time that get confused with each other. None of them is worked out from another.
Before anything is noticed.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before a test result moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
Before performance moves.RNAWiki does not store this separately, and never works it out from another figure on this page.
How long the result was watched.No finished study window is recorded for a study that tested this substance.
How long people took it.How long people actually took it is not stored. The study window is not the same thing.
How long people were followed.Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.
How fast the body clears it. 1.9 to 2.9 hours hours
Read from the label, which states: “Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.”
How long effects linger.RNAWiki does not store this separately, and never works it out from another figure on this page.
Beyond the studies. Nothing is recorded about the long term.
The longest finished study sets the edge of what anyone measured.
A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Adults and children from age 1 upwards with reflux or ulcer disease, and — through the over-the-counter version approved in 2009 — a large number of adults treating heartburn without a diagnosis.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “Therefore, safety and effectiveness have not been established in patients less than one year of age.”
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
On older people, the label states: “Of the total number of patients (n=21,486) in clinical studies of lansoprazole, 16% of patients were aged 65 years and over, while 4% were 75 years and over.”
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Available data from published observational studies overall do not indicate an association of adverse pregnancy outcomes with lansoprazole treatment (see Data).”
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary There is no information regarding the presence of lansoprazole in human milk, the effects on the breastfed infant, or the effects on milk production.”
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
On people with reduced liver function, the label states: “In patients with various degrees of chronic hepatic impairment the exposure to lansoprazole was increased compared to healthy subjects with normal hepatic function [see Clinical Pharmacology ( 12.3 )].”
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
Where the result stopped carrying
Lansoprazole monotherapy for Helicobacter pylori: 1 eradication in 53 patients, and 69% ulcer recurrence within six months
Infant reflux: no separation from placebo on any measure, and five times as many serious adverse events
Childhood asthma: nothing moved, and respiratory infections rose
Misoprostol outperformed it on the endoscopic ulcer endpoint it was licensed for
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
RNAWiki has not recorded a supervision or regulatory status for this substance.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
No register row and no identity class settled the question.
No source is stored against this line.
What is in the pack
Every form protects the drug from gastric acid, because the free base is destroyed by it within minutes.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold. The rest of the recorded wording: The orally disintegrating tablet exists so the drug can be given to small children and to people who cannot swallow capsules, without breaking the enteric coat — the tablet disperses while each microgranule inside it stays sealed.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
The label carries warnings for acute tubulointerstitial nephritis, Clostridioides difficile-associated diarrhoea, bone fracture with long-term high-dose use, cutaneous and systemic lupus erythematosus, cyanocobalamin deficiency, hypomagnesaemia, and fundic gland polyps with use beyond one year. Commonest trial adverse events are diarrhoea, abdominal pain, nausea and headache. The two placebo-controlled paediatric trials of this molecule both reported an excess of respiratory infection: relative risk 1.3 (95% CI 1.1 to 1.6) in 306 children, and serious adverse events dominated by lower respiratory tract infection in 10 of 81 infants against 2 of 81 (P=0.032).
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Lansoprazole appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 9434 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
A recorded note compares this form with the others that are sold. It is kept below, word for word.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
The recorded note, unchanged: The orally disintegrating tablet exists so the drug can be given to small children and to people who cannot swallow capsules, without breaking the enteric coat — the tablet disperses while each microgranule inside it stays sealed.
No source is stored against this line.
What is recorded as being sold
151 products list this as an active ingredient in the United States drug directory. 151 of them contain it and nothing else.
FDA National Drug Code directory · 72476-020 · read 2026-08-29
They are sold as capsule, delayed release, capsule, delayed release pellets, pellet, powder, tablet, orally disintegrating and tablet, orally disintegrating, delayed release, taken oral.
FDA National Drug Code directory · 72476-020 · read 2026-08-29
The regulator's established pharmacologic class for it is inhibition gastric acid secretion [pe], proton pump inhibitor [epc] and proton pump inhibitors [moa].
FDA National Drug Code directory · 72476-020 · read 2026-08-29
104 published labels name it as an active ingredient. 104 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-29
Those labels are classed as human otc drug and human prescription drug.
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-29
Lansoprazole is oral at 3 DOSAGE FORMS AND STRENGTHS Lansoprazole delayed-release capsules: 15 mg delayed-release capsules are opaque, hard gelatin, colored pink and green with the "264" imprinted on body in white ink. 30 mg delayed-release ca…, recorded as fda label in effect 2025-07-17 in the United States.
US prescribing information · 9e246e79-2737-4cbb-ad5d-4e76893da3be · read 2026-08-30
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
RNAWiki could not confidently classify this substance, so no self-experiment plan is offered.
Questions worth asking
Which of the trials of Lansoprazole studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That infant crying attributed to reflux responds to acid suppression, refuted by an exactly identical placebo response rate
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That treating silent reflux improves childhood asthma control, refuted including in the pH-documented subgroup
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That a proton pump inhibitor is the best available protection against NSAID ulcers, when the head-to-head comparator beat it on the endoscopic endpoint
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the adult placebo-controlled safety record of pantoprazole describes this molecule, or describes children
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Lansoprazole are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
On its own it eradicated the bacterium in 1 of 53 patients, and 69% had a recurrent ulcer
In plain words
The clearest demonstration anywhere that acid suppression treats the symptom and not the cause. Two weeks of lansoprazole alone cleared Helicobacter pylori in one patient out of fifty-three, and seven in ten of that group had an ulcer again within six months. Two weeks of lansoprazole with two antibiotics cleared it in 94% and only 7% relapsed.
What was measured
Helicobacter pylori eradication at 4 to 6 weeks and duodenal ulcer recurrence at six months, across six randomised regimens
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A double-blind, multicentre United States study randomised 396 patients with active or recent duodenal ulcer and Helicobacter pylori infection to one of six 14-day regimens, with 352 meeting entry criteria. At 4 to 6 weeks after the end of therapy, eradication was 94% (44 of 47) with lansoprazole, clarithromycin and amoxicillin; 77% with lansoprazole and amoxicillin three times daily; 75% with lansoprazole twice daily and clarithromycin three times daily; 57% and 53% with the twice-daily dual regimens; and 2% (1 of 53) with lansoprazole monotherapy. All comparisons P<=0.05. Among patients ulcer-free at 4 to 6 weeks, ulcers recurred within six months in 7% on triple therapy, 13 to 23% on dual therapy and 69% on lansoprazole alone. Patients Helicobacter-negative at 4 to 6 weeks relapsed in 11% of cases against 47% of those still positive.
Written into the record, not signed off as a reviewed claim
In crying infants it matched placebo exactly, and caused five times as many serious adverse events
In plain words
One hundred and sixty-two infants with persistent crying attributed to reflux were given lansoprazole or placebo for four weeks. Fifty-four per cent responded in each group — the same number, forty-four infants out of eighty-one, on both sides. Ten infants on the drug had a serious adverse event, mostly chest infections, against two on placebo.
What was measured
Proportion of infants with a 50% or greater reduction in feeding-related crying over four weeks, against matching placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
A multicentre, double-blind, parallel-group study randomised 162 infants aged 1 to 12 months whose symptoms attributed to gastro-oesophageal reflux disease had persisted despite at least a week of non-pharmacological management. The primary efficacy definition was a 50% or greater reduction in measures of feeding-related crying. Responders were 44 of 81 (54%) in each group — identical. No significant difference was detected in any secondary measure or analysis. Treatment-emergent adverse events occurred in 62% on lansoprazole against 46% on placebo (P=0.058). Serious adverse events, particularly lower respiratory tract infections, occurred in 12 infants and were significantly more frequent on lansoprazole, 10 against 2 (P=0.032).
Written into the record, not signed off as a reviewed claim
In 306 children with poorly controlled asthma it changed nothing and caused more infections
In plain words
Silent reflux is common in children with asthma and treating it was expected to help. Three hundred and six children on inhaled steroids took lansoprazole or placebo for 24 weeks. Asthma control did not improve, lung function did not improve, quality of life did not improve, and the children on the drug caught more respiratory infections.
What was measured
Change in Asthma Control Questionnaire score over 24 weeks, against matching placebo, with a prespecified pH-monitored subgroup
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
The Study of Acid Reflux in Children with Asthma randomised 306 children with poor asthma control despite inhaled corticosteroid treatment and without overt reflux symptoms, at 19 United States academic centres, to lansoprazole (15 mg daily under 30 kg, 30 mg at or above 30 kg; n=149) or placebo (n=157) for 24 weeks. Mean age was 11. The mean difference in change in Asthma Control Questionnaire score was 0.2 units (95% CI 0.0 to 0.3), against a 0.5-unit threshold for clinical meaning. No significant differences appeared in FEV1 (0.0 L, 95% CI -0.1 to 0.1), asthma-related quality of life (-0.1, 95% CI -0.3 to 0.1) or episodes of poor asthma control (relative risk 1.2, 95% CI 0.9 to 1.5). Among 115 children with oesophageal pH studies, 43% had reflux, and that subgroup showed no treatment effect on any asthma outcome. Children on lansoprazole reported more respiratory infections (relative risk 1.3, 95% CI 1.1 to 1.6).
Written into the record, not signed off as a reviewed claim
It lost the head-to-head against misoprostol for preventing NSAID ulcers
In plain words
Proton pump inhibitors are the standard way to protect the stomach from anti-inflammatory painkillers. In the trial that compared them directly, misoprostol left 93% of patients ulcer-free at twelve weeks against 80 to 82% on lansoprazole. Misoprostol also caused far more side effects, and once early withdrawals were counted as failures the two strategies came out level.
What was measured
Proportion free of endoscopic gastric ulcer at 12 weeks, against placebo and against misoprostol
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
A prospective, double-blind, multicentre, active- and placebo-controlled study enrolled 537 Helicobacter pylori-negative long-term NSAID users with a history of endoscopically documented gastric ulcer, randomising to placebo, misoprostol 200 micrograms four times daily, or lansoprazole 15 mg or 30 mg once daily for 12 weeks, with endoscopy at 4, 8 and 12 weeks. Gastric ulcer-free proportions at week 12 were 51% on placebo (95% CI 41.1 to 61.3), 93% on misoprostol (87.2 to 97.9), 80% on lansoprazole 15 mg (72.5 to 87.3) and 82% on lansoprazole 30 mg (75.0 to 89.6). Both lansoprazole arms beat placebo (P<0.001) and both were beaten by misoprostol. Significantly more misoprostol patients reported treatment-related adverse events and withdrew early; treating withdrawals as failures gave 69% success for each active treatment against 35% for placebo.
Written into the record, not signed off as a reviewed claim
Paediatric reflux treatment reversed direction once anyone ran a placebo arm
In plain words
Prescribing of acid suppressants to infants rose sharply through the 2000s on the reasoning that unexplained crying and back-arching were reflux. Two placebo-controlled trials, one in infants and one in children with asthma, found no benefit and more infections in both. The guidelines that followed reversed the recommendation.
What was measured
That infant crying and childhood asthma symptoms are caused by acid reflux and respond to acid suppression — an inference from prevalence and plausibility that two placebo-controlled trials refuted
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Two randomised, placebo-controlled trials of this molecule in children were published within three years. In 162 infants, response was 54% in both arms and serious adverse events, chiefly lower respiratory tract infections, were 10 against 2 (P=0.032). In 306 children with poorly controlled asthma, the Asthma Control Questionnaire difference was 0.2 units against a 0.5-unit threshold for clinical meaning, with a relative risk of 1.3 (95% CI 1.1 to 1.6) for respiratory infections on the drug. The infection signal is mechanistically coherent: gastric acid is a barrier to swallowed and aspirated organisms, and removing it in a small airway-prone child is not neutral. The field moved from treating infant irritability as reflux to reserving acid suppression for objectively documented disease, and both trials are cited in the guidelines that made that shift.
Written into the record, not signed off as a reviewed claim
The long-term safety data for this class is not lansoprazole’s
In plain words
The three-year randomised safety evidence that reassures people about proton pump inhibitors came from a trial of pantoprazole. Lansoprazole has no equivalent, and the one signal it has generated in its own randomised trials — more respiratory infections in children — points the same way as the gut-infection excess that trial did find.
What was measured
That the placebo-controlled adult safety record of pantoprazole describes lansoprazole, and describes children — two separate extrapolations, one of which the paediatric trials contradict
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
COMPASS randomised 17,598 adults to pantoprazole or placebo for a median of 3.01 years and found no significant excess of pneumonia, C. difficile, fracture, gastric atrophy, chronic kidney disease, dementia, cancer or death, with enteric infections at 1.4% against 1.0% (odds ratio 1.33, 95% CI 1.01 to 1.75). No placebo-controlled trial of comparable size exists for lansoprazole in adults. The paediatric trials of lansoprazole are the class’s only placebo-controlled randomised infection signals: relative risk 1.3 (95% CI 1.1 to 1.6) for respiratory infections in 306 children, and 10 against 2 serious adverse events dominated by lower respiratory tract infection in 162 infants. Reading the adult safety reassurance across to this molecule, and to children, is an inference in both directions.
This order is fixed in code and does not count clicks or time on the page.
What is not here
3 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A proton pump inhibitor that the stomach’s own acid converts into a molecule that welds itself shut onto the acid pump, and the one whose trials show most clearly what acid suppression cannot do: on its own it eradicated Helicobacter pylori in 2% of 53 patients and 69% of them had a recurrent ulcer within six months, while adding two antibiotics took eradication to 94% and recurrence to 7% — and in 162 crying infants and 306 wheezing children it performed identically to placebo while causing more respiratory infections in both.
Recorded evidence blocks (14)
Q1
What did Lansoprazole's largest trial (4238504 people) and its longest (10 years) measure?
4238504 people in Lansoprazole's largest registered study, 10 years in its longest registered window, measuring Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite. ClinicalTrials.gov · 2026-09-01
48 phase4, 44 phase3, 28 phase1, 17 phase2, 14 na, 7 na or unstated, 1 early phase1; NCT01506986; 2022-03-16; no ageing endpoint recorded. Last human test completed 2025, NCT05946135.
Interpretation These counts include studies where Lansoprazole was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase4
48
phase3
44
phase1
28
phase2
17
na
14
na or unstated
7
2 more recorded rows
early phase1
1
Last recorded human testNCT05946135
2025-09-08
recorded 2026-09-01 · last checked 2026-09-04
Q2
Lansoprazole was tested only in human — what did it show?
Interpretation Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite. — the recorded outcome words.
Show the evidence
humanNCT00942175
biomarker; Pharmacokinetic Parameter Peak Plasma Concentration (Cmax) of Clopidogrel's Active Metabolite.; 155
recorded 2026-09-01 · last checked 2026-09-04
Q3
18 of Lansoprazole's trials stopped: futility/efficacy, accrual/recruitment, funding/business, other?
futility/efficacy (1), accrual/recruitment (6), funding/business (1) and other (10): Lansoprazole's stop wording, clustered. ClinicalTrials.gov · 2026-09-01
"No enrollment."; 18 of 155 registered studies
Show the evidence
Trial
NCT00211614
withdrawn; "No enrollment."
NCT00220909
terminated; "Recruitment slow"
NCT00361972
terminated; "limited recruitment"
NCT00369265
terminated; "Pharmaceutical company purchased by another company and funding was terminated."
NCT00472186
terminated; "Poor compliance with returning of logbooks by families. Two patients were enrolled. Only one returned the logbook and therefore not analyzed"
NCT00637416
terminated; "Enrollment challenges"
12 further recorded trials
NCT00762359
terminated; "AG-1749 superior to Gefarnate in ulcer prevention"
NCT00837759
terminated; "Changes to study personnel."
NCT00857597
terminated; "Study was terminated after unplanned interim analysis of single centre data and results were reported"
NCT01040455
terminated; "failure to recruit enough patients"
NCT01123031
withdrawn; "The study was terminated and the PI has left the institution."
NCT02150447
terminated; "Low enroll rate"
NCT02873702
terminated; "Compound is not expected to change the current treatment practice or fill significant clinical need for patients in China over currently available EE agents."
NCT03059303
terminated; "Decision to discontinue development of investigational Hep C treatment regimen JNJ-4178: 3 direct acting antivirals - AL-335, ODV \& SMV."
NCT03355170
withdrawn; "The sponsor decided to continue with a different design and a different protocol."
NCT03468777
terminated; "The study has been terminated due to pending data analysis"
NCT03794596
withdrawn; "IP breach"
NCT04188119
withdrawn; "Unable to open"
recorded 2026-09-01 · last checked 2026-09-04
Q4
Human studies of Lansoprazole used Lansoprazole 30mg — over how long?
Lansoprazole's half-life is 1.9 to 2.9 hours — which schedules were studied?
1.9 to 2.9 hours, the half-life Lansoprazole's label states. openfda-label · 7a79feee-2e21-4cd0-a720-c59643764303 · 2026-08-30
bioavailability 80% %.
Show the evidence
half life
1.9 to 2.9 hours hours; Because the mean half-life in the elderly remains between 1.9 to 2.9 hours, repeated once daily dosing does not result in accumulation of lansoprazole.
tmax
The AUC for free lansoprazole in plasma, however, was not related to the degree of renal impairment; and the C max and T max (time to reach the maximum concentration) were not different than the C max and T max from subjects with normal renal function.
bioavailability
80% %; The absolute bioavailability is over 80%.
metabolism
Plasma protein binding is constant over the concentration range of 0.05 to 5 mcg/mL. Elimination Metabolism Lansoprazole is extensively metabolized in the liver.
recorded 2026-08-30 · last checked 2026-09-04
Q6
Could one person measure Lansoprazole's effect on pharmacokinetic analysis?
Pharmacokinetic analysis: measured in Lansoprazole's trials.
Interpretation pharmacokinetic analysis is the recorded endpoint.
Show the evidence
biomarkers
pharmacokinetic analysis; 2026-09-01
intragastric 24 hour ph; 2026-09-01
lymphocyte count; 2026-09-01
time to analgesia; 2026-09-01
pain reduction; 2026-09-01
c peptide; 2026-09-01
14 more recorded rows
biomarkers
gerd symptoms; 2026-09-01
biomarkers
cmax; 2026-09-01
biomarkers
auc0 t; 2026-09-01
biomarkers
auc0 inf; 2026-09-01
biomarkers
2 hour c peptide auc in response to mmtt; 2026-09-01
biomarkers
recurrent ulcer bleeding; 2026-09-01
biomarkers
bioequivalence based on cmax and auc parameters; 2026-09-01
biomarkers
incidence of treatment emergent adverse events; 2026-09-01
biomarkers
eradication rate of helicobacter pylori; 2026-09-01
biomarkers
frequency of adverse drug reactions; 2026-09-01
biomarkers
serum urate 5 0 / at month 3; 2026-09-01
biomarkers
reporting one or more adverse drug reactions; 2026-09-01
biomarkers
reporting one or more serious adverse drug reactions; 2026-09-01
biomarkers
area under the concentration time curve; 2026-09-01
half life
2026-09-04; halfLife; hours; 1.9 to 2.9 hours; 2026-08-30
human trials at or under30
34
smallest human trial
0; NCT00211614; NA; the smallest recorded human enrolment at or below 30; the registry states no direction of its result; WITHDRAWN
Q7
Which of 2 hour c peptide auc in response to mmtt, adverse effects after genotype guided ppi therapy and area under the concentration time curve did Lansoprazole's trials measure?
2 hour c peptide auc in response to mmtt, adverse effects after genotype guided ppi therapy and area under the concentration time curve lead 39 outcome terms across Lansoprazole's trials. ClinicalTrials.gov · 2026-09-01
time to analgesia, pain reduction, c peptide, gerd symptoms, cmax and auc0 t follow.
Show the evidence
pharmacokinetic analysis
1
intragastric 24 hour ph
1
lymphocyte count
1
time to analgesia
1
pain reduction
1
c peptide
1
14 more recorded rows
gerd symptoms
1
cmax
1
auc0 t
1
auc0 inf
1
2 hour c peptide auc in response to mmtt
1
recurrent ulcer bleeding
1
bioequivalence based on cmax and auc parameters
1
incidence of treatment emergent adverse events
1
eradication rate of helicobacter pylori
1
frequency of adverse drug reactions
1
serum urate 5 0 / at month 3
1
reporting one or more adverse drug reactions
1
reporting one or more serious adverse drug reactions
1
area under the concentration time curve
1
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which of Lansoprazole's 11 ongoing trials reports first?
Absolute change in percent predicted (%) forced vital capacity (FVC); Percentage of persistently-infected teenagers which change UBT status from positive to negative 1 month post-treatment, as compared to non-treated subjects.; latest 2028-12-31
Show the evidence
Trial
NCT04965298
"Treating People With Idiopathic Pulmonary Fibrosis With the Addition of Lansoprazole"; n 298; "Absolute change in percent predicted (%) forced vital capacity (FVC)"; 2026-02-28
NCT05926804
"A "Screen and Treat" Helicobacter Pylori Eradication Trial in Adolescents in Three Regions of Chile"; n 500; "Percentage of persistently-infected teenagers which change UBT status from positive to negative 1 month post-treatment, as compared to non-treated subjects."; 2027-08
NCT06284876
"Study to Evaluate the Efficacy and Safety of Ilaprazole 10 mg in Prevention NSAIDs Associated Peptic Ulcer"; n 416; "Ilaprazole, Lansoprazole peptic ulcer"; 2027-02-28
NCT06894992
"Tegoprazan And Lansoprazole Effectiveness in Bleeding Peptic Ulcer Treatment"; n 162; "Healing Rate"; 2025-12-31
NCT06931223
"Efficacy of Gut-Brain Neuromodulators for Functional Dyspepsia"; n 200; "Leuven Postprandial Distress Scale (LPDS) score"; 2025-09-10
NCT06964334
"The Effect of Vitamin D Supplement as Adjuvant Therapy in Eradication of Helicobacter Pylori Infection"; n 70; "cure rate after treatment"; 2026-08-01
5 further recorded trials
NCT07479056
"Fexuprazan for Prevention of Upper Gastrointestinal Bleeding in High Bleeding Risk Patients Receiving Dual Antiplatelet Therapy"; n 400; "Time from randomization to first occurrence of a composite endpoint of upper gastrointestinal clinical events during the treatment period"; 2028-12-31
NCT07533266
"Study to Evaluate the Efficacy and Safety of Fexuprazan in Prevention of NSAIDs Induced Peptic Ulcer"; n 360; "Proportion of subjects who develop peptic ulcer by Week 24 as assessed by investigator"; 2027-12
NCT07708545
"Tegoprazan Versus Lansoprazole for Endoscopic Ulcer Healing in Bleeding Peptic Ulcers"; n 162; "Mucosal Healing Rate"; 2027-02-28
NCT07730138
"Phase 3 to Evaluate the Efficacy and Safety of DWP14012 in Patients With Gastric Ulcer"; n 384; "Cumulative gastric ulcer healing rate confirmed by upper gastrointestinal endoscopy through Week 8"; 2028-10-15
NCT07732075
"Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 as Maintenance Therapy in Subjects With Healed Erosive Esophagitis"; n 384; "The proportion of subjects with maintained healing of erosive esophagitis confirmed by upper gastrointestinal endoscopy at Week 24"; 2028-10-30
recorded 2026-09-01 · last checked 2026-09-04
Q9
Which 65 trials of Lansoprazole posted no result?
Posted no result
65 of 65 completed trials
Registrations
NCT00637845, NCT00641602, NCT00175045, NCT00644735, NCT00625274 and NCT00220818, and 59 more
Completion dates
oldest 2003-02; newest 2024-07-19
Show the evidence
Trial
NCT00637845
2003-02
NCT00641602
2003-08
NCT00175045
2003-10
NCT00644735
2004-01
NCT00625274
2004-11
NCT00220818
2005-07
14 further recorded trials
NCT00174928
2005-08
NCT00230516
2006-02
NCT00390390
2007-01
NCT00352261
2007-04
NCT00458614
2007-04
NCT00410592
2007-05
NCT00701259
2007-08
NCT00471094
2007-10
NCT00239551
2007-12
NCT00864396
2008-05
NCT01270308
2008-12
NCT00663897
2009-09
NCT00952913
2009-10
NCT01039558
2011-03
Q10
At the median, Lansoprazole's trials enrolled 120 people — anything larger?
Median enrolment
120
Largest enrolment
4238504
Registered trials counted
155
Q11
What do 9434 spontaneous reports say about Lansoprazole — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Lansoprazole appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 9434 reaction mentions were counted: chronic kidney disease 2737; acute kidney injury 1772; hyponatraemia 1171; renal failure 873. open-targets-adr · CHEMBL480 · 2026-06-24
Show the evidence
chronic kidney disease
2737
acute kidney injury
1772
hyponatraemia
1171
renal failure
873
renal injury
646
end stage renal disease
642
4 more recorded rows
hypomagnesaemia
505
tubulointerstitial nephritis
382
hypocalcaemia
359
gastrooesophageal reflux disease
347
recorded 2026-06-24 · last checked 2026-09-04
Q12
Lansoprazole and CYP2C19, CYP1A2 and CYP2C9: shared by which compounds?
CYP2C19, CYP1A2 and CYP2C9 appear in Lansoprazole's recorded interaction sentences, 10 in all. openfda-label+europepmc · 2026-08-30
Interpretation pharmacokinetics
Show the evidence
CYP1A2
pharmacokinetics
These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
pharmacokinetics
Theophylline: When lansoprazole was administered concomitantly with theophylline (CYP1A2, CYP3A), a minor increase (10%) in the clearance of theophylline was seen.
CYP2C19
pharmacokinetics
Drug Interaction Studies Effect of Lansoprazole on Other Drugs Cytochrome P450 Interactions: Lansoprazole is metabolized through the cytochrome P450 system, specifically through the CYP3A and CYP2C19 isozymes.
pharmacokinetics
These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
pharmacokinetics
Clopidogrel: Clopidogrel is metabolized to its active metabolite in part by CYP2C19.
pharmacokinetics
A study of healthy subjects who were CYP2C19 extensive metabolizers, receiving once daily administration of clopidogrel 75 mg alone or concomitantly with lansoprazole 30 mg (n=40), for nine days was conducted.
pharmacokinetics
Effect of Other Drugs on Lansoprazole Because lansoprazole is metabolized by CYP2C19 and CYP3A4, inducers and inhibitors of these enzymes may potentially alter exposure of lansoprazole.
CYP2C9pharmacokinetics
These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
CYP2D6pharmacokinetics
These compounds are metabolized through various cytochrome P450 isozymes including CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A.
CYP3A4pharmacokinetics
Effect of Other Drugs on Lansoprazole Because lansoprazole is metabolized by CYP2C19 and CYP3A4, inducers and inhibitors of these enzymes may potentially alter exposure of lansoprazole.
recorded 2026-08-30 · last checked 2026-09-04
Q13
Was Lansoprazole studied with fasting?
fasting is named in Lansoprazole's label sentences: "A research trial was conducted to determine whether medication with an acid secretion inhibitor (lansoprazole), either alone or in combination with an antibiotic (azithromycin), would protect pigs from gastric ulceration if the animals were subjected to a 48 h period of fasting." openfda-label+europepmc · 2026-08-30
1 recorded statement; fasting
Show the evidence
fasting
A research trial was conducted to determine whether medication with an acid secretion inhibitor (lansoprazole), either alone or in combination with an antibiotic (azithromycin), would protect pigs from gastric ulceration if the animals were subjected to a 48 h period of fasting.
recorded 2026-08-30 · last checked 2026-09-04
Q14
What is recorded about Lansoprazole and mTOR?
"Furthermore, we explored combination therapy strategies and found that Lansoprazole synergizes with everolimus, an established mTOR inhibitor used in PanNEN treatment." — where Lansoprazole and mTOR appear together. Europe PMC · pathway abstract search · 2026-04-01
"Furthermore, we explored combination therapy strategies and found that Lansoprazole synergizes with everolimus, an established mTOR inhibitor used in PanNEN treatment."
"Tetrahydrofolate, maprotiline, and the combination of aspirin and lansoprazole emerged as top candidates for PTL prevention, delaying labor onset primarily through enhanced mTOR signaling in innate immune cells and attenuated JAK/STAT signaling in naïve CD4⁺ T cells."
NAD+PMID 37384717
"Lansoprazole treatment of rat liver epithelial RL34 cells induced transactivation of Nrf2 and the expression of the Nrf2-dependent antioxidant genes encoding HO1, NAD(P)H quinone oxidoreductase-1, and glutathione S-transferase A2."
AMPKPMID 33641315
"The lansoprazole and albendazole treatments can be a potential drug or combined with antidiabetic drugs in T2D treatment by Adenosine 5′-monophosphate activated protein kinase (AMPK), peroxisome proliferator-activated receptor (PPAR), incretin-like effect and other antidiabetic mechanisms."
mTORPMID 29746821
"In renal cells, lansoprazole's anti-proliferative effect was mediated by inhibition of mTOR/S6K and extracellular signal-regulated kinase (ERK) signaling proteins."
recorded 2026-04-01 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.